Amgen Dismisses Bone Density Concerns Related to Its New Weight-Loss Drug
(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...
Wolfe Research starts Amgen at Peer Perform given approaching patent cliffs
Wolfe Research analyst Alexandria Hammond initiated coverage of Amgen (AMGN) with a Peer Perform rating. With the antibody backbone, the firm ...
clinicaltrialsarena16h
Amgen speaks out about bone density concerns with obesity drug
Amgen has spoken out about concerns related to bone mineral density (BMD) loss with its obesity candidate after an analyst’s comment caused a $12bn market wipe.
2 Dividend Stocks to Buy Hand Over Fist in November
2 Dividend Stocks to Buy Hand Over Fist in November was originally published by The Motley Fool Their recent issues are ...
Amgen Shrugs Off Bone Density Concerns Related to Obesity Candidate
Amgen refutes in a press release that its trial obesity drug, MariTide, may cause bone loss density. Amgen's stock has risen 4.6% this year against a decrease of 3.8% for the pharmaceuticals industry.
STAT18h
AbbVie’s stumble, Amgen’s tumble, and more election fallout
On STAT's podcast, hear about what happened with AbbVie's schizophrenia drug, Amgen's obesity drug and what might happen at ...
Gilead, Vertex initiated as new big biotech buys at Citi
Citi has started coverage of Gilead Sciences (NASDAQ:GILD) and Vertex Pharmaceuticals (NASDAQ:VRTX) at buy saying the former will benefit from short-term growth of Biktarvy (bictegravir, emtricitabine ...
Wall Street Indexes Dip With Focus on Trump Policies, Economic Data
The Dow Jones Industrial Average fell 382.15 points, or 0.86%, to 43,910.98, the S&P 500 lost 17.36 points, or 0.29%, to ...
Citi initiates coverage on 5 new biotech stocks
Citigroupa expanded its biotech coverage on Wednesday, adding five more stocks to the roster including Amgen (NASDAQ:AMGN), Biogen (NASDAQ:BIIB), Gilead (NASDAQ:GILD), Regeneron (NASDAQ:REGN), and ...